Adrenoleukodystrophy Market, Size, Share, Trends, Epidemiology Forecast till 2030

July 29 02:56 2020
Adrenoleukodystrophy Market, Size, Share, Trends, Epidemiology Forecast till 2030

DelveInsight Business Research LLP
DelveInsight’s “Adrenoleukodystrophy Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Adrenoleukodystrophy , historical and forecasted epidemiology as well as the Adrenoleukodystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Adrenoleukodystrophy (ALD) is an X-linked recessive genetic disorder caused by the abnormality in the ABCD1 gene present on the X chromosome that leads to the accumulation of very-long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland.

 

Epidemiology Insights

  • Total prevalent population of ALD in the 7MM in 2017 was 55,242
  • The prevalent population of ALD in the US was 19,371 in 2017
  • Among the EU5, Germany had the highest diagnosed prevalent population of ALD with 1,699 cases
  • The highest diagnosed prevalence of ALD was in the United States in 2017 was 4,885

 

Adrenoleukodystrophy Market Size in the United States in 2017 was USD 523.26 million

 

Scope of the Report

  • The report covers the descriptive overview of Adrenoleukodystrophy , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Adrenoleukodystrophy epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Adrenoleukodystrophy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Adrenoleukodystrophy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Adrenoleukodystrophy market

 

Adrenoleukodystrophy Market Drivers

  • Increased number of potential therapies in the pipeline
  • Awareness about newborn screening programs
  • Increase in the number of Childhood Cerebral Adrenoleukodystrophy (CALD) cases

 

Adrenoleukodystrophy Emerging Therapies

  1. Lenti D: bluebird bio
  2. Leriglitazone: Minoryx Therapeutics, S.L.
  3. MD1003: MedDay Pharmaceuticals
  4. MGTA-456: Magenta Therapeutics
  5. OP-101: Orpheris Inc.
  6. SOM1201: SOM Biotech

Request for sample pages

 

 

Table of contents

1. Key Insights

2. Adrenoleukodystrophy (ALD): Market Overview at a Glance

2.1. Total Market Share (%) Distribution of ALD in 2017

2.2. Total Market Share (%) Distribution of ALD in 2030

3. Adrenoleukodystrophy: Disease Background and Overview

3.1. Introduction

3.2. Clinical aspects of ALD

3.3. Causes of ALD

3.4. Inheritance pattern of ALD

3.5. ALD-Symptoms

3.6. Pathogenesis and Pathophysiology of ALD

3.7. Diagnosis

3.7.1. ALD Newborn Screening

3.7.2. Tools for evaluating Cerebral ALD

3.7.3. Diagnostic algorithm

3.7.4. HSCT and presymptomatic diagnosis of ALD in Japan

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. Epidemiology Methodology

4.3. KOL Views

4.4. Total Prevalent Population of Adrenoleukodystrophy in the 7MM

5. United States Epidemiology

5.1. Assumptions and Rationale

5.2. Total Prevalent Population of Adrenoleukodystrophy (ALD) in the United States

5.3. Gender-specific Prevalence of Adrenoleukodystrophy in the United States

5.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the United States

5.5. Type-specific Diagnosed Prevalence of ALD in Males in the United States

6. EU5 Epidemiology

6.1. Germany Epidemiology

6.1.1. Assumptions and Rationale

6.1.2. Total Prevalent Population of Adrenoleukodystrophy in Germany

6.1.3. Gender-specific Prevalence of Adrenoleukodystrophy in Germany

6.1.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Germany

6.1.5. Type-specific Diagnosed Prevalence of ALD in males in Germany

6.2. France Epidemiology

6.2.1. Assumptions and rationale

6.2.2. Total Prevalent Population of Adrenoleukodystrophy in France

6.2.3. Gender-specific Prevalence of Adrenoleukodystrophy in France

6.2.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in France

6.2.5. Type-specific Diagnosed Prevalence of ALD in Males in France

6.3. Italy Epidemiology

6.3.1. Assumptions and Rationale

6.3.2. Total Prevalent Population of Adrenoleukodystrophy in Italy

6.3.3. Gender-specific Prevalence of Adrenoleukodystrophy in Italy

6.3.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Italy

6.3.5. Type-specific Diagnosed Prevalence of ALD in Males in Italy

6.4. Spain Epidemiology

6.4.1. Assumptions and Rationale

6.4.2. Total Prevalent Population of Adrenoleukodystrophy in Spain

6.4.3. Gender-specific Prevalence of Adrenoleukodystrophy in Spain

6.4.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Spain

6.4.5. Type-specific Diagnosed Prevalence of ALD in Males in Spain

6.5. United Kingdom Epidemiology

6.5.1. Assumptions and Rationale

6.5.2. Total Prevalent Population of Adrenoleukodystrophy in the United Kingdom

6.5.3. Gender-specific Prevalence of Adrenoleukodystrophy in the United Kingdom

6.5.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the United Kingdom

6.5.5. Type-specific Diagnosed Prevalence of ALD in Males in the United Kingdom

7. Japan Epidemiology

7.1. Assumptions and Rationale

7.2. Total Prevalent Population of Adrenoleukodystrophy in Japan

7.3. Gender-specific Prevalence of Adrenoleukodystrophy in Japan

7.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Japan

7.5. Type-specific Diagnosed Prevalence of ALD in Males in Japan

8. Current Treatment and Medical Practices

8.1. Subtype-specific Treatment

8.2. Treatment Guidelines

8.2.1. Recommendations for Treatment of X-linked ALD in the United States

8.2.2. Adrenoleukodystrophy treatment: European Leukodystrophies Association

8.3. Early intervention and long-term follow-up system for presymptomatic ALD patients in Japan

9. Unmet Needs

10. Emerging Therapies

10.1. Lenti D: bluebird bio

10.1.1. Drug Description

10.1.2. Regulatory Milestone

10.1.3. Other Development Activities

10.1.4. Clinical Development

10.1.5. Safety and Efficacy

10.1.6. Advantages and Disadvantages

10.1.7. Product Profile

10.2. Leriglitazone: Minoryx Therapeutics, S.L.

10.2.1. Drug Description

10.2.2. Regulatory Milestones

10.2.3. Other Development Activities

10.2.4. Clinical Development

10.2.5. Safety and Efficacy

10.2.6. Advantages and Disadvantages

10.2.7. Product Profile

10.3. MD1003: MedDay Pharmaceuticals

10.3.1. Drug Description

10.3.2. Other Development Activities

10.3.3. Clinical Development

10.3.4. Safety and Efficacy

10.3.5. Advantages and Disadvantages

10.3.6. Product Profile

10.4. MGTA-456: Magenta Therapeutics

10.4.1. Product Description

10.4.2. Other Development Activities

10.4.3. Clinical Development

10.4.4. Clinical Trial Update

10.4.5. Safety and Efficacy

10.4.6. Product Profile

10.5. OP-101: Orpheris Inc.

10.5.1. Drug Description

10.5.2. Regulatory Milestones

10.5.3. Other Development Activities

10.5.4. Clinical Development

10.5.5. Product Profile

10.6. SOM1201: SOM Biotech

10.6.1. Product Description

10.6.2. Other Development Activities

10.6.3. Product Profile

11. Failed Therapy

11.1. NV1205: NeuroVia/Archer Daniels Midland

11.1.1. Drug Description

11.1.2. Other Development Activities

11.1.3. Clinical Development

11.1.4. Safety and Efficacy

11.1.5. Advantages and Disadvantages

11.1.6. Product Profile

12. Adrenoleukodystrophy (ALD): 7MM Market Analysis

12.1. Key Findings

12.2. Market Methodology

12.3. Market Size of Adrenoleukodystrophy in the 7MM

12.4. Market Size of Adrenoleukodystrophy by Therapies in the 7MM

13. 7MM: Market Outlook

14. United States

14.1. United States Market Size

14.1.1. Total Market size of Adrenoleukodystrophy in the United States

14.1.2. Market Size of Adrenoleukodystrophy by Therapies in the US

15. EU-5 countries

15.1. Germany Market Size

15.1.1. Total Market size of Adrenoleukodystrophy in Germany

15.1.2. Market Size of Adrenoleukodystrophy by therapies in Germany

15.2. France Market Size

15.2.1. Total Market size of Adrenoleukodystrophy in France

15.2.2. Market Size of Adrenoleukodystrophy by therapies in France

15.3. Italy Market Size

15.3.1. Total Market size of Adrenoleukodystrophy in Italy

15.3.2. Market Size of Adrenoleukodystrophy by therapies in Italy

15.4. Spain Market Size

15.4.1. Total Market size of Adrenoleukodystrophy in Spain

15.4.2. Market Size of Adrenoleukodystrophy by therapies in Spain

15.5. United Kingdom Market Size

15.5.1. Total Market size of Adrenoleukodystrophy in the United Kingdom

15.5.2. Market Size of Adrenoleukodystrophy by therapies in the UK

16. Japan

16.1. Japan Market Size

16.1.1. Total Market size of Adrenoleukodystrophy in Japan

16.1.2. Market Size of Adrenoleukodystrophy by therapies in Japan

17. Market Drivers

18. Market Barriers

19. Appendix

19.1. Bibliography

19.2. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

 

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/